The Medical Letter on Drugs and Therapeutics
An Imaging Agent for Amyloid
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.

IMAGING — Florbetapir binds to fibrillary β-amyloid found in neuritic plaques.1,2 After IV injection, scans with more radioactivity in white matter than in adjacent cortical gray matter display clear gray-white contrast and are interpreted as negative. Scans with one or more areas of significantly more radioactivity in gray matter than in adjacent white matter show a reduction or loss of gray-white differentiation and are considered positive.

SENSITIVITY AND SPECIFICITY — Among 29 terminally ill patients who had florbetapir-PET imaging, 15 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: An Imaging Agent for Amyloid
Article code: 1394b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian